Profile of clinically-diagnosed dementias in a neuropsychiatric practice in Abeokuta, South-Western Nigeria

G Amoo¹, RO Akinyemì²,³, LU Onofa¹, JO Akinyemì³, O Baiyewu⁴, AO Ogunlesi¹, A Ogunniyi⁶
¹Psychogeriatrics Unit, Aro Neuropsychiatric Hospital, Abeokuta, Nigeria
²Division of Neurology, Department of Medicine, Federal Medical Centre, Abeokuta, Nigeria
³Department of Epidemiology and Biostatistics, College of Medicine, University of Ibadan, Ibadan, Nigeria
⁴Department of Psychiatry, University College Hospital, Ibadan, Nigeria
⁵Department of Medicine, University College Hospital, Ibadan, Nigeria
⁶Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL, UK

Abstract

Objective: Many subjects with dementia present primarily to neuropsychiatric practices because of behavioural and psychological symptoms (BPSD). This study reviewed the profile of clinically-diagnosed dementias and BPSD seen in a pioneer neuropsychiatric practice in Abeokuta, southwestern Nigeria over a ten year period (January 1998 – December 2007). Methods: A review of hospital records of all patients with diagnoses of dementia or dementing illness using the ICD-10 criteria as well as specific diagnostic criteria for different dementia phenotypes. Associated BPSD, co-morbidities and treatments were also reviewed. Results: Out of a total of 240,294 patients seen over the study period, 108 subjects met clinical diagnostic criteria for probable dementia giving a hospital frequency of 45 per 100,000. Alzheimer’s disease (AD) and Vascular dementia (VaD) were the predominant phenotypes seen in 62 (57.4%) and 18 (16.7%) subjects respectively. Others include mixed dementia (4 cases), frontotemporal dementia (4 cases), Lewy body dementia (3 cases), alcohol-related dementia (3 cases), PD dementia (1 case) and unclassifiable (13 cases). Apathy, nighttime behaviour, aberrant motor behaviour, agitation and irritability were the most common BPSD features, while hypertension was the most common co-morbidity. Neuroleptics, anticholinergics and anti-hypertensives were most commonly prescribed. Anticholinesterase inhibitors were sparingly used. Conclusion: Probable AD was the most prevalent dementia phenotype seen in this practice. Increased awareness of dementia and better utilization of specific treatments are needed among psychiatrists and primary care practitioners in Nigeria.

Keywords: Dementia phenotypes; BPSD; Neuropsychiatric practice; Nigeria; Africa

Received: 20-10-2010
Accepted: 11-01-2011
doi: http://dx.doi.org/10.4314/ajpsy.v14i5.5

Introduction

Dementia, a mental health disorder of global public health concern, is defined as a considerable decline in cognitive function that is severe enough to impair the ability to perform personal activities of daily living.¹ In the mid-80s, dementia was thought to be rare in developing countries including Nigeria¹–³, however recent estimates in 2007 suggested that about 33 million people worldwide, 60-70% of whom resided in developing countries including Africa, suffered from dementia while the total cost of ageing-related dementias exceeded US$ 70 billion.¹ And, though the burden of dementia is currently low in sub-Saharan Africa, population ageing, lifestyle changes, increasing vascular factors, poverty, malnutrition, wars and the HIV pandemic may cause future increments.⁵
From community-based studies, the prevalence of dementia in Nigeria ranges between 2.29% and 2.79% with Alzheimer’s disease (AD), whose prevalence ranges between 1.41% and 1.86%, being the most common type. However, in a previous retrospective study of clinically-diagnosed dementing illnesses in Ibadan, 37 cases of dementia diagnosed according to the ICD-9 and DSM-III criteria were seen over a six year period (1984 – 1989) out of a total of 57,440 cases admitted, giving an average hospital frequency of 64 cases per 100,000 admissions. Majority of the cases (48.7%) had vascular dementia while secondary dementias (metabolic/toxic, subdural haematoma, organ failure) constituted 21.6%. Thirteen percent of cases were mixed dementias while primary degenerative dementias constituted only 2.7%. Associated morbidities included hypertension, diabetes mellitus, Parkinsonism and benign prostatic hypertrophy. In a similar hospital-based study from Kinshasa, Democratic Republic of Congo, 35 cases of dementia were diagnosed over a ten year period (1990-2000) with 42.8% being vascular dementia while 22.8% were AD.

Behavioural and psychological symptoms of dementia (BPSD) are common manifestations and may be the presenting symptom or appear in the course of dementia. They include delusions/paranoia, visual and auditory hallucinations, dysphoria, anxiety, agitation/agresssion, euphoria, disinhibition, irritability, apathy, aberrant motor behaviour such as wandering, night-time behavior including sleep alterations, incontinence, depression, phobias, poor eating habits and schizophreniform/paranoid psychosis. Behavioural and psychological symptoms of dementia (BPSD) in the domains of the NPI-Q was noted but the retrospective nature of the study precluded the determination of the severity of the symptoms as well as distress in the caregivers/informant.

A comprehensive symptom check list was generated for assessing the domains represented in the Neuropsychiatric Inventory - Questionnaire (NPI-Q) and applied retrospectively to all the cases meeting the criteria for probable dementia. The frequency of occurrence of BPSD in the domains of the NPI-Q was noted but the retrospective nature of the study precluded the determination of the severity of the symptoms as well as distress in the caregivers/informant.

Methods

We obtained data from hospital records of all patients with a provisional diagnosis of dementing illness or dementia managed at the Aro Neuropsychiatric Hospital, Abeokuta, Southwestern Nigeria over a ten year period. The frequency and types of dementing illnesses as well as the characteristics of BPSD, co-morbidities and treatment modalities were assessed.

Results

Hospital frequency of dementia

Over the 10-year period, a total of 240,294 patients presented to the hospital, of which 125 received a diagnosis of dementing illness. However, only 108 subjects met the ICD-10 criteria for clinical diagnosis of probable dementia, giving an average hospital frequency of 45 cases per 100,000 patients. Seventeen patients were excluded and their diagnoses were: depressive illness (4), delirium (2), schizophrenia (2) and unclassified psychotic disorder (9).

The 108 patients diagnosed with dementia consisted of 51 (47.2%) males and 57 (52.8%) females, age [mean (SD) 70.1 (9.8) years, median 70, range 44 to 101]. Ten patients were younger than 60 years of age while 43 (39.8%) were in the 60–69 years age range. Majority were married (63.5%), had no formal education (63.0%), were of Yoruba ethnic extraction (96.3%), were retired (98.1%), lived with others (93.5%) and were seen on an outpatient basis (86.1%).

Dementia phenotypes

Table I shows the distribution, demographic and clinical features of the different dementia phenotypes seen among the subjects. AD predominated with 62 cases (57.4%) while...
VaD was diagnosed in 18 cases (16.7%). Others included mixed dementia (4 cases [3.7%]), FTD (4 cases [3.7%]), DLB (3 cases [2.8%]), alcohol-related dementia (3 cases [2.8%]), and PDD (1 case [0.9%]). In 13 cases (12.0%), lack of relevant neuroimaging, biochemical and haematological investigations precluded the determination of more specific dementia diagnoses. Mild, moderate and severe dementia were present in 10 (9.3%), 47 (43.5%) and 51 (47.2%) of the subjects respectively. The CDR ratings according to phenotypes are also summarized in the second panel of Table I.

### Clinical characteristics of the dementia phenotypes

The mean age of onset among subjects with AD was 71.2 ± 9.4 years and majority of subjects (44/62) were older than 70 years ($\chi^2 = 19.5, p = 0.001$). There was a statistically significant female preponderance [male to female ratio 0.63:1, $x^2 = 4.23, p = 0.04$] as well as a significant preponderance of persons with no formal education ($x^2 = 8.88, p = 0.031$). Subjects with AD were significantly older than subjects with other dementia subtypes ($T = 3.61, P < 0.001$). Among subjects with VaD, mean age of onset was 62.8 ± 8.7 years with a significantly higher male proportion [male to female ratio 2.6:1, $x^2 = 5.41, p = 0.02$]. The mean age of onset for subjects with mixed dementia was 64.6 ± 5.4 years with equal gender balance. The mean ages of onset for other phenotypes were: FTD (65 ± 17.1 years); alcohol-related dementia (64.9 ± 14.6 years); PDD (69.5 years) and DLB (64.1 ± 5.0 years).

Impairment of recent memory was the most common cognitive symptom recorded across the different phenotypes. Table I shows the spectrum of other cognitive symptoms.

### Table I: Demographic and clinical features of subjects according to Dementia phenotype

<table>
<thead>
<tr>
<th>Variable</th>
<th>AD (n=62)</th>
<th>VaD (n=18)</th>
<th>Mixed D (n=4)</th>
<th>FTD (n=4)</th>
<th>DLB (n=3)</th>
<th>AlcD (n=3)</th>
<th>PDD (n=1)</th>
<th>Unclassified (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (SD) years</td>
<td>72.8 (9.4)</td>
<td>64.5 (8.7)</td>
<td>66.3 (5.4)</td>
<td>69.3 (17.1)</td>
<td>65.0 (5.0)</td>
<td>66.3 (14.6)</td>
<td>70.0 (0)</td>
<td>67.4 (9.1)</td>
</tr>
<tr>
<td>Median duration of symptoms (range) mths</td>
<td>14 (4-99)</td>
<td>23 (3-79)</td>
<td>16 (3-57)</td>
<td>64 (39-73)</td>
<td>13 (7-15)</td>
<td>37 (7-37)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender: n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>24 (38.7)</td>
<td>13 (72.2)</td>
<td>2 (50.0)</td>
<td>2 (60.0)</td>
<td>-</td>
<td>3 (100.0)</td>
<td>1 (100.0)</td>
<td>6 (46.2)</td>
</tr>
<tr>
<td>Female</td>
<td>38 (61.3)</td>
<td>5 (27.8)</td>
<td>2 (50.0)</td>
<td>2 (60.0)</td>
<td>3 (100.0)</td>
<td>-</td>
<td>-</td>
<td>7 (53.8)</td>
</tr>
<tr>
<td>Level of Education: n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>46 (74.2)</td>
<td>9 (50.0)</td>
<td>2 (50.0)</td>
<td>1 (25.0)</td>
<td>3 (100.0)</td>
<td>-</td>
<td>3 (100.0)</td>
<td>1 (100.0)</td>
</tr>
<tr>
<td>At least primary</td>
<td>16 (25.8)</td>
<td>9 (50.0)</td>
<td>2 (50.0)</td>
<td>3 (75.0)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7 (53.8)</td>
</tr>
<tr>
<td>Clinical Dementia Rating (CDR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild (0.5-1)</td>
<td>5 (8.1)</td>
<td>1 (5.6)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2 (15.4)</td>
<td></td>
</tr>
<tr>
<td>Moderate (2.0)</td>
<td>28 (45.2)</td>
<td>5 (27.8)</td>
<td>2 (50.0)</td>
<td>2 (50.0)</td>
<td>1 (25.0)</td>
<td>3 (100.0)</td>
<td>1 (100.0)</td>
<td>6 (46.2)</td>
</tr>
<tr>
<td>Severe (3.0)</td>
<td>27 (44.0)</td>
<td>12 (66.7)</td>
<td>3 (75.0)</td>
<td>1 (25.0)</td>
<td>1 (25.0)</td>
<td>1 (33.3)</td>
<td>2 (66.7)</td>
<td>5 (38.4)</td>
</tr>
<tr>
<td>Cognitive symptoms [n (%)]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impairment of recent memory</td>
<td>58 (93.5)</td>
<td>14 (77.8)</td>
<td>4 (100.0)</td>
<td>4 (100.0)</td>
<td>3 (100.0)</td>
<td>3 (100.0)</td>
<td>3 (100.0)</td>
<td>13 (100.0)</td>
</tr>
<tr>
<td>Language problems</td>
<td>54 (87.1)</td>
<td>14 (77.8)</td>
<td>2 (50.0)</td>
<td>3 (100.0)</td>
<td>3 (100.0)</td>
<td>3 (100.0)</td>
<td>3 (100.0)</td>
<td>8 (61.5)</td>
</tr>
<tr>
<td>Visuospatial dysfunction</td>
<td>48 (77.4)</td>
<td>7 (38.9)</td>
<td>2 (50.0)</td>
<td>1 (25.0)</td>
<td>1 (25.0)</td>
<td>1 (33.3)</td>
<td>1 (33.3)</td>
<td>7 (53.8)</td>
</tr>
<tr>
<td>Attentional deficits</td>
<td>49 (79.0)</td>
<td>12 (66.7)</td>
<td>3 (75.0)</td>
<td>3 (75.0)</td>
<td>3 (100.0)</td>
<td>2 (66.7)</td>
<td>1 (33.3)</td>
<td>10 (76.9)</td>
</tr>
<tr>
<td>Disorientation in time</td>
<td>47 (75.8)</td>
<td>13 (72.2)</td>
<td>2 (50.0)</td>
<td>4 (100.0)</td>
<td>3 (100.0)</td>
<td>2 (66.7)</td>
<td>1 (33.3)</td>
<td>9 (69.2)</td>
</tr>
<tr>
<td>Difficulty recognizing faces</td>
<td>55 (88.7)</td>
<td>11 (61.1)</td>
<td>2 (50.0)</td>
<td>3 (75.0)</td>
<td>3 (100.0)</td>
<td>3 (100.0)</td>
<td>3 (100.0)</td>
<td>8 (61.5)</td>
</tr>
<tr>
<td>Medical Co-morbidities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension (BP &gt; 140/90mmHg) n (%)</td>
<td>17 (27.4)</td>
<td>17 (94.4)</td>
<td>3 (75.0)</td>
<td>-</td>
<td>1 (33.3)</td>
<td>1 (33.3)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stroke</td>
<td>-</td>
<td>13 (72.2)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>3 (4.8)</td>
<td>2 (11.1)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1 (33.3)</td>
<td>-</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>5 (8.1)</td>
<td>1 (5.6)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1 (100.0)</td>
<td>-</td>
</tr>
</tbody>
</table>

AD: Alzheimer’s disease; VaD: Vascular dementia; FTD: Frontotemporal dementia; AlcD: Alcohol-related dementia; PDD: Parkinson’s disease dementia
Other co-morbidities include: DM (6), hearing impairment (4), visual impairment (2), post-stroke seizure disorder (1), post-stroke parkinsonism (1).
Table II: Profile of BPSD and Dementia phenotype based on the Neuropsychiatry Inventory-Questionnaire (NPI –Q) schema

<table>
<thead>
<tr>
<th>BPSD</th>
<th>Baiyewu et al (n=40)</th>
<th>AD (n=62)</th>
<th>VaD (n=18)</th>
<th>Mixed D (n=4)</th>
<th>FTD (n=4)</th>
<th>DLB (n=3)</th>
<th>AllocD (n=3)</th>
<th>PDD (n=1)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delusions/Paranoia</td>
<td>7 (17.5)</td>
<td>22 (35.5)</td>
<td>2 (11.1)</td>
<td>1 (25.0)</td>
<td>-</td>
<td>1 (33.3)</td>
<td>1 (33.3)</td>
<td>-</td>
<td>0.197</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>5 (12.5)</td>
<td>16 (25.8)</td>
<td>2 (11.1)</td>
<td>1 (25.0)</td>
<td>2 (50.0)</td>
<td>3 (100.0)</td>
<td></td>
<td>1 (100.0)</td>
<td>0.244</td>
</tr>
<tr>
<td>Dysphoria/Depression</td>
<td>13 (32.5)</td>
<td>16 (25.8)</td>
<td>2 (11.1)</td>
<td>2 (50.0)</td>
<td>1 (25.0)</td>
<td>-</td>
<td></td>
<td>2 (100.0)</td>
<td>0.042*</td>
</tr>
<tr>
<td>Apathy</td>
<td>8 (20.0)</td>
<td>4 (6.5)</td>
<td>2 (11.1)</td>
<td>1 (25.0)</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>0.488</td>
</tr>
<tr>
<td>Agitation/Aggression</td>
<td>8 (20.0)</td>
<td>38 (61.3)</td>
<td>4 (22.2)</td>
<td>2 (50.0)</td>
<td>2 (50.0)</td>
<td>1 (33.3)</td>
<td>2 (66.7)</td>
<td></td>
<td>0.610</td>
</tr>
<tr>
<td>Euphoria</td>
<td>4 (10.0)</td>
<td>3 (4.8)</td>
<td>1 (5.6)</td>
<td>-</td>
<td>-</td>
<td>1 (33.3)</td>
<td>-</td>
<td>-</td>
<td>0.385</td>
</tr>
<tr>
<td>Disturbion</td>
<td>4 (10.0)</td>
<td>24 (38.7)</td>
<td>10 (55.6)</td>
<td>3 (75.0)</td>
<td>-</td>
<td>-</td>
<td>1 (33.3)</td>
<td>-</td>
<td>0.000*</td>
</tr>
<tr>
<td>Irritability</td>
<td>11 (27.5)</td>
<td>32 (51.6)</td>
<td>4 (22.2)</td>
<td>2 (50.0)</td>
<td>2 (50.0)</td>
<td>1 (33.3)</td>
<td>2 (66.7)</td>
<td></td>
<td>0.733</td>
</tr>
<tr>
<td>Apathy</td>
<td>10 (25.0)</td>
<td>54 (87.1)</td>
<td>14 (77.3)</td>
<td>3 (75.0)</td>
<td>2 (50.0)</td>
<td>3 (100.0)</td>
<td>1 (33.3)</td>
<td>1 (100.0)</td>
<td>0.024*</td>
</tr>
<tr>
<td>Aberrant motor behaviour</td>
<td>3 (7.5)</td>
<td>48 (77.4)</td>
<td>7 (38.9)</td>
<td>2 (50.0)</td>
<td>1 (25.0)</td>
<td>1 (33.3)</td>
<td>1 (33.3)</td>
<td></td>
<td>0.016*</td>
</tr>
<tr>
<td>Night-time behaviour</td>
<td>7 (17.5)</td>
<td>50 (80.6)</td>
<td>10 (55.6)</td>
<td>2 (50.0)</td>
<td>4 (100.0)</td>
<td>3 (100.0)</td>
<td>1 (33.3)</td>
<td></td>
<td>0.002*</td>
</tr>
</tbody>
</table>

*Baiyewu et al (2003) studied 40 community-dwelling subjects with dementia (AD = 39; 1 = non-specific dementia) [13]

*chi-square test of association between BPSD and severity of dementia on the Clinical Dementia Rating (CDR) scale.

*Value of p < 0.05 (statistically significant).

Spectrum of behavioural and psychological symptoms (BPSD)

Table II shows the spectrum of BPSD documented among subjects with the various dementia phenotypes using the Neuropsychiatric Inventory (NPI) schema in comparison with the profile obtained by Baiyewu et al among 40 community-dwelling residents with dementia (largely AD).13 Apathy was the most common BPSD across all the phenotypes, documented in 87.1%, 77.8% and 75% of subjects with AD, VaD and mixed dementia respectively. Hallucinations (visual) were documented in 87.1%, 77.8% and 75% of subjects with AD, VaD and mixed dementia respectively. The majority of the patients, 104 (96.3%), received antipsychotic medications (chlorpromazine, trifluoperazine, thioridazine, risperidone, haloperidol, flupenthixol, fluphenazine decanoate) while 36 (33.3%) and 13 (12.0%) received anticholinergic (benzhexol, biperiden) and antidepressant (amitriptyline, imipramine, paroxetine, moclobemide, sertraline) drugs respectively. Only 1 subject received an anticholinesterase inhibitor (donepezil). Forty-two (38.9%) and 12 (11.1%) subjects received antihypertensive (amlodipine, nifedipine, alpha methyl dopa, amiloride + hydrochlorothiazide (moduretic), reserpine + clopamide + dihydroergocristine (brinerdin) and anti-diabetic (glibendamide, metformin and insulin) agents respectively.

Discussion

This study revealed a rather low hospital frequency of dementia. While this may be a reflection of the current low prevalence of dementia among the Nigerian elderly population, it may also be due to low case ascertainment and the culture of regarding early features of dementia as part of normal ageing with hospital presentation becoming necessary only when moderate to severe BPSD set in, and overwhelm the relatives and caregivers.

The predominant dementia phenotype was AD followed by VaD unlike findings from similar retrospective hospital-based studies from Ibadan and Kinshasa respectively which reported preponderance of VaD. We attribute this to the treatment seeking behaviour of subjects with VaD presenting to physicians/neurologists in conventional hospitals (such as those involved in the Ibadan and Kinshasa studies) on account of variable neurologic deficits associated with vascular events even before the onset of cognitive symptoms. On the other hand, patients with degenerative dementias such as AD (especially moderate to severe cases) might have presented to the neuropsychiatric hospital on account of significant BPSD that had become distressing for the family and caregivers to cope with. The relationship between age and gender, and AD and VaD in this study is in accordance with previous reports. However, whereas previous studies from Nigeria found no significant relationship between education and AD and lack of formal education. This is in accordance with the protective role of education against dementia by enhancing cognitive reserve.

Dementia with Lewy bodies and FTD have been reported among Nigerians and prominent BPSD similarly might have accounted for the cases seen in this study. Alcohol use is quite low in Nigeria largely because of religious reasons and most patients with Parkinson’s disease are seen in neurology practices. These may account for the relatively low frequencies of dementias related to alcohol and PD in this cohort.

Memory symptoms are often regarded as part of normal ageing in many African cultures and medical attention is sought only when BPSD become worrisome. This might explain the long duration of symptoms before presentation in hospital in
search of treatment as well as the fact that majority of the patients were already in moderate to severe stages of the disease before medical attention was sought.

The prevalence of BPSD was quite high in this cohort, and frequencies were higher than those reported earlier by Baiyewu et al in a cohort of community-dwelling dementia subjects (predominantly AD) of similar ethnic and cultural background but similar to high rates reported in some western outpatient dementia clinics and nursing homes. Apathy, night-time behavior (poor sleep), aberrant motor behavior (wandering), depression and disinhibition – all potentially distressing and embarrassing behaviors – were the BPSD most associated with the severity of the disease in our subjects. This agreed with the findings of Baiyewu et al (2003) who also observed BPSD being associated more with moderate-severe distress among caregivers of the community-dwelling cohort. This could, therefore, explain why subjects in the hospital cohort were brought to the neuropsychiatric hospital by their caregivers/relatives in the first place.

In the Yoruba culture, elderly subjects usually live in multi-generational extended family systems where they receive a lot of stimulation and care from the younger family members. In this study, about 95% of our subjects lived with others, especially their children.

A relatively high proportion of our subjects were hypertensive (94.4% and 27.4% respectively among subjects with VaD and AD) while 11.1% were diabetic. Hypertension and other vascular factors are important in the aetiopathogenesis of both AD and VaD. Populations with higher burden of vascular risk factors have been shown to have higher burden of both AD and VaD compared to populations of similar genetic stock but with lower burden of vascular risk factors. Signiﬁcant vascular pathologies including haemorrhages, inﬁrcts, small vessel pathologies and white matter changes have been documented in brain tissues of subjects with VaD and AD. Studies have also demonstrated increased deposition and decreased clearance of amyloid β, microangiopathy, neuronal loss and macrovascular cerebral disease in association with DM.

Evidence similarly exists showing that effective control of vascular risk factors especially from mid-life results in signiﬁcant reduction in the burden of AD and VaD.

Typical antipsychotic medications for BPSD constituted the majority of medications prescribed for subjects in our study cohort. Although a recent guideline advocates the use of an atypical antipsychotic agent, quetiapine, in the management of BPSD, it is very expensive and largely unavailable and unaffordable in low resource settings including Nigeria. And, even though AD was the predominant dementia phenotype seen in this study, only one patient received donepezil. We attribute this to several factors including: problems of availability, accessibility, affordability as well as possible poor awareness of dementia management among the treatment providers during the period covered by the study. Dementia-specific continuous medical educational programmes are needed among GPs, Internists and Psychiatrists to enhance their knowledge, conﬁdence and skills in the detection and management of dementia. It is also important to make speciﬁc dementia medications available and affordable in developing countries which are likely to bear the lion share of future increments in the global burden of dementia.

Although the majority (>95%) of patients in this study lived with relations, especially children, current trends show that the traditional multi-generational extended family system is already being eroded as a result of increasing urbanization and globalization. It is therefore pertinent to evolve policies and strategies to care for the increasing population of the elderly, especially, in the developing economies of Africa. New approaches to the delivery of basic, accessible, affordable and appropriate geriatric health care are needed.

This study represents the first attempt at reviewing the proﬁle of dementias in a neuropsychiatric hospital practice across sub-Saharan Africa using standardized clinical diagnostic criteria, and it shows that subjects with dementia (predominantly AD and VaD) are seen; BPSDs are more common than in population-based cohorts; hypertension is the most signiﬁcant medical co-morbidity and signiﬁcant dementia –speciﬁc treatment gap exists.

The study, however, has limitations. Its retrospective design did not allow for more rigorous and exhaustive diagnostic procedures in the subjects diagnosed with dementia. Also, none of the diagnoses was conﬁrmed at autopsy and objective cognitive assessment tools were not routinely used in assessing the patient population. Further prospective, multi-centre studies are needed as well as speciﬁc manpower development in Psychogeriatrics in order to enhance early detection and appropriate management of dementias in general medical and psychiatric practices across Africa.

Conclusion

Our study provides data on the proﬁle of dementias as seen in a black African neuropsychiatric practice and demonstrates that AD and VaD are the most common phenotypes similar to ﬁndings from population-based studies from developing and developed regions. The burden of BPSD appears to be higher in hospital-based than community-based cohorts. Hypertension is an important co-morbidity and signiﬁcant treatment gap exists in dementia phenotype-speciﬁc treatments.

References

8. Oggunnyi AO, Lekwauwa RG, Falope JF, Osuntokun BO. Clinically